Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBP-089
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
KBP-089 is a novel dual amylin and calcitonin receptor agonist (DACRA) developed for the treatment of obesity and type 2 diabetes mellitus. It acts as an agonist at both the amylin receptor and the calcitonin receptor, leading to weight loss primarily through reduction in fat mass while preserving or slightly increasing lean mass. In preclinical studies, KBP-089 demonstrated significant suppression of food intake, improved glucose tolerance with lowered plasma insulin levels, reduced gastric emptying rate, and altered food preference towards healthier options. The drug is administered via subcutaneous injection[1][3][9][10]. Developed by KeyBioscience (KeyBioScience AG) and later licensed to Eli Lilly and Company for further development[4].
- Other names
- DACRA 089DACRA089DACRA-089
02
Targets
AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)
Beyond the preview
Go deeper on KBP-089.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBP-089.